Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TUCSON, Ariz. , May 24, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that on May 22, 2019 the Compensation Committee of its Board of Directors granted inducement stock options to
Toggle Summary HTG Molecular Diagnostics Reports First Quarter 2019 Results
Call scheduled for today, May 9, at 4:30pm ET TUCSON, Ariz. , May 09, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended March 31, 2019
Toggle Summary HTG Molecular Diagnostics to Announce First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9
TUCSON, Ariz. , April 30, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the first quarter ended March 31, 2019 after the market close on
Toggle Summary HTG Molecular Expands Agreement with Illumina to Include Autoimmune, Cardiovascular, and Fibrosis Disorders and Diseases
Amendment allows for the development of IVD test kits compatible with Illumina technology TUCSON, Ariz. , April 30, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it has amended its
Toggle Summary HTG Introduces the HTG EdgeSeq Mouse mRNA Tumor Response Panel
TUCSON, Ariz. , March 27, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it has released a new HTG EdgeSeq Mouse mRNA Tumor Response Panel available now in the United States and

Stock Chart

SEC Filings

Filing date Description